Solutions for MSCs Immunomodulation in TME

Relying on the technology platform of the tumor microenvironment center, Alfa Cytology provides global collaborators with solutions and related services to study the immunomodulatory mechanisms of mesenchymal stem cells (MSC) in the tumor microenvironment (TME), helping them to rapidly achieve their research goals.

Introduction

Mesenchymal stem cells (MSC) in the tumor microenvironment (TME) can exercise their immunomodulatory role through direct cell-to-cell contact and secretory effect secretion of bioactive factors, such as growth factors, cytokines and chemokines. For example, MSCs interact with macrophages and up-regulate the expression of molecules related to phagocytosis in macrophages, which makes macrophages enhance the phagocytosis of microorganisms and reduce the further stimulation of immune cells by invading microorganisms. Mesenchymal stem cells (MSC) can also effectively inhibit the over-activation of T cells, which can reduce the number of T cells by inhibiting the formation of antigen-presenting cells-dendritic cells (DCs) from peripheral blood mononuclear cells (PBMC) and suppressing lymphocyte proliferation. It can also inhibit the over-activation of T cells by directly regulating the content of the activated subpopulation of T cells. Mesenchymal stem cells (MSC) can upregulate treg cells to suppress the release of the pro-inflammatory factor IFN-g and upregulate Th2 to promote the release of the anti-inflammatory factor IL-4, thereby stimulating the body's immune system's own regulatory capacity.

Solutions

The immune system itself has certain regulatory ability, mainly relying on T helper cells, such as Treg and Th17, etc. Mesenchymal stem cells in the tumor microenvironment (TME) can influence these cells to improve the regulatory ability of the immune system. The immunomodulatory effects of MSCs are increasingly used in a wide range of applications, such as neocoronavirus pneumonia, GvHD, systemic lupus erythematosus, inflammatory bowel disease, and allergic rhinitis. With their low immunogenicity and modulation of innate and acquired immunity, MSCs are able to control overactive immune responses with almost no side effects and achieve the function of treating many immune-related diseases. Alfa Cytology has established a tumor microenvironment technology platform and developed several emerging technologies through which it helps global collaborators to deeply explore the immune regulatory role of tumor microenvironment mesenchymal stem cells (MSCs) and their mechanisms, hoping to find potential targets for tumor therapy in the process and provide new ideas for clinical anti-tumor treatment.

Key technologies

The mass spectrometry flow technique breaks through the technical bottleneck of traditional flow cytometry by using metal isotopes as the probe to couple antibodies, and then using inductively coupled plasma mass spectrometry (ICP-MS) instead of lasers and photomultiplier tubes as the detection system. MS detects the metal isotope signals of coupled antibodies, allowing the simultaneous detection of more than 40 parameters at the single cell level. To study the phenotype, composition and dynamic changes of immune cells in MSCs transplanted animal models to precisely reveal the immunomodulatory mechanisms of MSCs.

Monoclonal antibody-based immunohistochemical detection. Monoclonal antibody binds to MSCs with high specificity and sensitivity, and can be stably applied to detect MSCs by immunoenzymatic cytochemical staining, indirect immunofluorescence staining, flow cytometry, and immunoblotting.

Alfa Cytology is committed to supporting scientists in making breakthrough scientific discoveries and developing new applications to accelerate new drug discovery and scientific diagnosis and treatment. Our high-performance scientific instruments and high-value solutions enable scientists to explore the mysteries of life at the tumor microenvironment level. Please tell us your project requirements, and we will provide you with a full service from solution to report. If you have any questions, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.